title: [Retinal vein occlusion: anti-VEGF treatments].
abstract: To date, there is no consistently effective proven therapy for patients with macular edema resulting from central retinal vein occlusion. Grid laser treatment only showed visual acuity benefit in branch retinal vein occlusion. Other treatment like intravitreal triamcinolone acetonide demonstrated transient inconsistent benefit with potential complications. As retinal vein occlusion is associated with increased levels of Vascular Endothelial Growth Factor (VEGF), anti-VEGF therapy was proposed to be a promising strategy for retinal vein occlusion. We reviewed the current literature on this topic: case reports, non controlled and non randomized trials. Short term results are encouraging with visual acuity benefit associated with reduction of retinal central thickness but multiple injections seems to be necessary to achieve visual stabilization. Further randomized and controlled clinical trials are necessary to confirm the long term safety and efficacy of bevacizumab in the care of retinal vein occlusion edema treatment.
authors.affiliation: Centre ophtalmologique d'imagerie et de laser, Paris, France. buffet.nghiem@free.fr
authors.forename: S
authors.initials: S
authors.lastname: Nghiem-Buffet
authors.forename: S-Y
authors.initials: SY
authors.lastname: Cohen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D000068258:Bevacizumab; D001813:Blood-Retinal Barrier; D002986:Clinical Trials as Topic; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology; D011446:Prospective Studies; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide; D000069579:Ranibizumab